WallStSmart

Evolent Health Inc (EVH)vsVeeva Systems Inc Class A (VEEV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Veeva Systems Inc Class A generates 65% more annual revenue ($3.46B vs $2.10B). VEEV leads profitability with a 29.3% profit margin vs -24.1%. VEEV appears more attractively valued with a PEG of 1.23. VEEV earns a higher WallStSmart Score of 66/100 (B-).

EVH

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 2.0Value: 4.7Quality: 3.5
Piotroski: 4/9Altman Z: -0.57

VEEV

Strong Buy

66

out of 100

Grade: B-

Growth: 8.7Profit: 8.0Value: 6.7Quality: 9.0
Piotroski: 4/9Altman Z: 4.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EVH.

VEEVUndervalued (+41.2%)

Margin of Safety

+41.2%

Fair Value

$301.18

Current Price

$262.40

$38.78 discount

UndervaluedFair: $301.18Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVH2 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
46.9%10/10

Revenue surging 46.9% year-over-year

VEEV6 strengths · Avg: 8.8/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.7810/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
29.3%9/10

Keeps 29 of every $100 in revenue as profit

Operating MarginProfitability
29.6%8/10

Strong operational efficiency at 29.6%

Revenue GrowthGrowth
17.6%8/10

17.6% revenue growth

EPS GrowthGrowth
39.5%8/10

Earnings expanding 39.5% YoY

Areas to Watch

EVH4 concerns · Avg: 3.3/10
PEG RatioValuation
1.934/10

Expensive relative to growth rate

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$508.77M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-131.8%2/10

ROE of -131.8% — below average capital efficiency

VEEV1 concerns · Avg: 2.0/10
P/E RatioValuation
43.4x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : EVH

The strongest argument for EVH centers on Price/Book, Revenue Growth. Revenue growth of 46.9% demonstrates continued momentum.

Bull Case : VEEV

The strongest argument for VEEV centers on Debt/Equity, Altman Z-Score, Profit Margin. Profitability is solid with margins at 29.3% and operating margin at 29.6%. Revenue growth of 17.6% demonstrates continued momentum.

Bear Case : EVH

The primary concerns for EVH are PEG Ratio, EPS Growth, Market Cap. Debt-to-equity of 2.53 is elevated, increasing financial risk.

Bear Case : VEEV

The primary concerns for VEEV are P/E Ratio. A P/E of 43.4x leaves little room for execution misses.

Key Dynamics to Monitor

EVH profiles as a hypergrowth stock while VEEV is a growth play — different risk/reward profiles.

VEEV carries more volatility with a beta of 0.97 — expect wider price swings.

EVH is growing revenue faster at 46.9% — sustainability is the question.

VEEV generates stronger free cash flow (231M), providing more financial flexibility.

Bottom Line

VEEV scores higher overall (66/100 vs 52/100), backed by strong 29.3% margins and 17.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evolent Health Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides healthcare delivery and payment solutions in the United States. The company is headquartered in Arlington, Virginia.

Visit Website →

Veeva Systems Inc Class A

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.

Visit Website →

Want to dig deeper into these stocks?